Elevating Patient Care: Senderra Specialty Pharmacy Adds EBGLYSS™ (lebrikizumab-lbkz), Lilly's First-Line Biologic Treatment for Moderate-to-Severe Atopic Dermatitis, to SenderraCare+ for a Streamlined, Empowering Digital Patient Experience

SenderraCare+ redefines specialty therapy by consolidating enrollment, adherence support, and medication management into one intuitive, in real-time digital platform. It accelerates treatment initiation, enhances patient compliance, drastically cuts abandonment, and empowers patients and...